-
Neurogene (NGNE) PT Lowered to $60 at BMO Capital
-
BMO Capital Reiterates Outperform Rating on Neurogene (NGNE)
-
BMO Capital Reiterates Outperform Rating on Neurogene (NGNE)
-
BMO Capital Reiterates Outperform Rating on Neurogene (NGNE)
-
BMO Capital Starts Neurogene (NGNE) at Outperform

